New antibody WIN378 aims to tame COPD lung inflammation
Disease control
Recruiting now
This phase 2 trial is testing a new medicine called WIN378 for people with moderate to severe COPD. WIN378 is a long-acting antibody that blocks a protein involved in lung inflammation. The study will test different doses in 105 adults who are former smokers and already on standa…
Phase: PHASE2 • Sponsor: Windward Bio • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC